-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson - TREMFYA reached primary and critical secondary endpoints in axial psoriatic arthritis research.

Zhitongcaijing·09/25/2026 11:33:11
Listen to the news
Johnson & Johnson - TREMFYA reached primary and critical secondary endpoints in axial psoriatic arthritis research.